AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12033092 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8%
Number of subjects: 35
Study 12033092 — intervention group
Group type: COMPARATOR
Intervention: Propofol 3 mg.kg‐1 and fentanyl 2 micrograms.kg‐1
Number of subjects: 35
Study 10087242 — intervention group
Group type: EXPERIMENTAL
Intervention: Prempak C 0.625(R) hormone replacement therapy
Number of subjects: 0
Study 10087242 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 8649914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised budesonide (2 mg)
Number of subjects: 80
Study 8649914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone syrup (0.6 mg/kg)
Number of subjects: 80
Study 8649914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 2315072 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottle feeding avoided in Weeks 2-6 postpartum
Number of subjects: 128
Study 2315072 — intervention group
Group type: COMPARATOR
Intervention: Approximately one bottle per day given during Weeks 2-6 postpartum
Number of subjects: 128
Study 7018726 — intervention group
Group type: EXPERIMENTAL
Intervention: MER (methanol extraction residue BCG) immunotherapy during chemotherapy
Number of subjects: 167
Study 7018726 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (CVPP or BAVS or alternating cycles of CVPP and BAVS)
Number of subjects: 167
Study 7018726 — intervention group
Group type: EXPERIMENTAL
Intervention: MER for patients with at least one pretreatment positive skin test
Number of subjects: 167
Study 31733004 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast culture (YC) fermented for 12, 24, 36, 48 or 60 hr
Number of subjects: 350
Study 31733004 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast culture (YC) fermented for 24 hr
Number of subjects: 350
Study 31733004 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast culture (YC) fermented for 60 hr
Number of subjects: 350
Study 31733004 — intervention group
Group type: COMPARATOR
Intervention: Basal diet without YC supplementation
Number of subjects: 350
Study 31733004 — intervention group
Group type: COMPARATOR
Intervention: Commercial YC product (SZ2)
Number of subjects: 350
Study 31084533 — intervention group
Group type: EXPERIMENTAL
Intervention: IDS-1L with one layer of adhesive
Number of subjects: 48
Study 31084533 — intervention group
Group type: EXPERIMENTAL
Intervention: IDS-2L with two layers of adhesive
Number of subjects: 48
Study 31084533 — intervention group
Group type: EXPERIMENTAL
Intervention: IDS-F with one layer of adhesive and one layer of flowable RBC
Number of subjects: 48
Study 31084533 — intervention group
Group type: COMPARATOR
Intervention: DDS (delayed dentin sealing) with no layer of adhesive (control)
Number of subjects: 48
Study 31084533 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-P with pumice rubbing
Number of subjects: 48
Study 31084533 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-PC with pumice rubbing followed by tribochemical silica coating
Number of subjects: 48
Study 29084522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 10,000 IU daily
Number of subjects: 40
Study 29084522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23637005 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin (rhTPO)
Number of subjects: 49
Study 23637005 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 25012990 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide before breakfast
Number of subjects: 0
Study 25012990 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide before main meal
Number of subjects: 0
Study 25012990 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22806399 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg twice per day
Number of subjects: 204
Study 22806399 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 40 mg once per day
Number of subjects: 204
Study 22806399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 22806399 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg twice per day (treatment-extension phase)
Number of subjects: 204
Study 22806399 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 40 mg once per day (treatment-extension phase)
Number of subjects: 204
Study 22806399 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo re-randomized to apremilast (treatment-extension phase)
Number of subjects: 204
Study 19708095 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized patients (241 out of 502 eligible)
Number of subjects: 502
Study 19708095 — intervention group
Group type: COMPARATOR
Intervention: Overall population of operated patients (1309)
Number of subjects: 502
Study 17549325 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Disability Index
Number of subjects: 102
Study 17549325 — intervention group
Group type: EXPERIMENTAL
Intervention: Northwick Park Pain Questionnaire
Number of subjects: 102
Study 17549325 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Neck Functional Disability Scale
Number of subjects: 102
Study 17549325 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Pain and Disability Scale
Number of subjects: 102
Study 16447934 — intervention group
Group type: EXPERIMENTAL
Intervention: VISX Star S2 excimer laser (n = 22)
Number of subjects: 43
Study 16447934 — intervention group
Group type: COMPARATOR
Intervention: Asclepion-Meditec MEL 70 G Scan excimer laser (n = 21)
Number of subjects: 43
Study 15547304 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis during cardiopulmonary resuscitation
Number of subjects: 0
Study 11120434 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary reinforcement
Number of subjects: 40
Study 11120434 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial feedback
Number of subjects: 40
Study 11120434 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reinforcement and facial feedback
Number of subjects: 40
Study 11120434 — intervention group
Group type: COMPARATOR
Intervention: Repeated practice
Number of subjects: 40
Study 8782347 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (720 ELISA units of antigen) administered according to the abbreviated schedule (two vaccinations given 2 weeks apart)
Number of subjects: 2036
Study 8782347 — intervention group
Group type: COMPARATOR
Intervention: Inactivated hepatitis A vaccine (720 ELISA units of antigen) administered according to the standard schedule (two vaccinations given 4 weeks apart)
Number of subjects: 2036
Study 8782347 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (720 ELISA units of antigen)
Number of subjects: 2036
Study 8782347 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (720 ELISA units of antigen) with other 'travellers' vaccines
Number of subjects: 2036
Study 1509550 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Diprivan) with prior administration of 4 micrograms/kg fentanyl
Number of subjects: 96
Study 1509550 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Diprivan) without prior administration of fentanyl
Number of subjects: 96
Study 6838691 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and/or drugs
Number of subjects: 40
Study 6838691 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study 6838691 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment patients
Number of subjects: 40
Study 6838691 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterioration in tests
Number of subjects: 40
Study 6838691 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 40
Study 30690546 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual chest percussion technique
Number of subjects: 46
Study 30690546 — intervention group
Group type: COMPARATOR
Intervention: Mechanical chest wall vibrator
Number of subjects: 46
Study 30690546 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 46
Study 27280502 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain management protocol for pancreatoduodenectomy (PD) with selective drain placement and early drain removal based on risk stratification.
Number of subjects: 260
Study 26198893 — intervention group
Group type: EXPERIMENTAL
Intervention: Illusory kinesthesia group
Number of subjects: 26
Study 26198893 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 24949549 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD-melon concentrate (10 mg per day for 12 weeks)
Number of subjects: 61
Study 24949549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch only for 12 weeks)
Number of subjects: 61
Study 23176987 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 204
Study 23176987 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation (TT)
Number of subjects: 204
Study 19399705 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) nifedipine; 20 mg loading dose, repeated in 30 minutes, daily 120 to 160 mg slow-release nifedipine for 48 hours followed by 80 to 120 mg daily until 36 weeks
Number of subjects: 102
Study 19399705 — intervention group
Group type: COMPARATOR
Intervention: Low-dose (LD) nifedipine; 10 mg, up to four doses every 15 minutes, daily 60 to 80 mg slow-release nifedipine for 48 hours followed by 60 mg daily until 36 weeks
Number of subjects: 102
Study 17353978 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic fundoplication (RALF)
Number of subjects: 40
Study 17353978 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic fundoplication (CLF)
Number of subjects: 40
Study 14996412 — intervention group
Group type: EXPERIMENTAL
Intervention: Yun Zhi (50 mg/kg body weight) plus Danshen (20 mg/kg body weight) capsules
Number of subjects: 100
Study 14996412 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 100
Study 11430277 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE instruction, personalized strategies to reduce barriers, monthly telephone reminders for 3 months
Number of subjects: 198
Study 9481579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 0
Study 9481579 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone
Number of subjects: 0
Study 9481579 — intervention group
Group type: COMPARATOR
Intervention: Oestrogen only phase
Number of subjects: 0
Study 8060466 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine-tryptophan-ketoglutarate (HTK) solution
Number of subjects: 60
Study 8060466 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 60
Study 3382247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (0.5 ppm)
Number of subjects: 41
Study 3382247 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 41
Study 31424395 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06751979 275 mg QD
Number of subjects: 0
Study 31424395 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06751979 50 mg QD
Number of subjects: 0
Study 31424395 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06751979 125 mg QD
Number of subjects: 0
Study 31424395 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06751979 540 mg single dose
Number of subjects: 0
Study 31424395 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06751979 275 mg multiple doses
Number of subjects: 0
Study 31424395 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06751979 100 mg QD
Number of subjects: 0
Study 28510491 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/FORM 100/10 μg b.i.d. with AeroChamber Plus® Flow‐Vu® Spacer
Number of subjects: 48
Study 28510491 — intervention group
Group type: COMPARATOR
Intervention: FP pMDI (Flixotide®) 100 μg b.i.d. with Volumatic® spacer
Number of subjects: 48
Study 28510491 — intervention group
Group type: COMPARATOR
Intervention: Extra-fine BDP breath-actuated inhaler (Aerobec®/QVAR® Autohaler®) 100 μg b.i.d.
Number of subjects: 48
Study 27163964 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple-fleshed potato meal
Number of subjects: 0
Study 27163964 — intervention group
Group type: COMPARATOR
Intervention: Yellow-fleshed potato meal
Number of subjects: 0
Study 27163964 — intervention group
Group type: COMPARATOR
Intervention: Bilberry meal
Number of subjects: 0
Study 23972645 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated mini‐tablets
Number of subjects: 306
Study 23972645 — intervention group
Group type: COMPARATOR
Intervention: Syrup
Number of subjects: 306
Study 23972645 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated mini‐tablet
Number of subjects: 306
Study 21431422 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed guilty participants
Number of subjects: 0
Study 21431422 — intervention group
Group type: COMPARATOR
Intervention: Informed innocent participants
Number of subjects: 0
Study 21431422 — intervention group
Group type: EXPERIMENTAL
Intervention: Less explicit information
Number of subjects: 0
Study 19141998 — intervention group
Group type: EXPERIMENTAL
Intervention: FX60 dialyser
Number of subjects: 33
Study 19141998 — intervention group
Group type: COMPARATOR
Intervention: HF80 dialyser
Number of subjects: 33
Study 17823672 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (1 mL injected into the joint space)
Number of subjects: 40
Study 17823672 — intervention group
Group type: COMPARATOR
Intervention: Saline (1 mL injected into the joint space)
Number of subjects: 40
Study 15559732 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of coping strategies for arm shock
Number of subjects: 0
Study 15559732 — intervention group
Group type: COMPARATOR
Intervention: No choice of coping strategies for arm shock
Number of subjects: 0
Study 12351466 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein 30 g/day, isoflavones 132 mg/day
Number of subjects: 32
Study 10399205 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust and model-based versions of score test and Wald test for assessing proportional odds
Number of subjects: 0
Study 10399205 — intervention group
Group type: EXPERIMENTAL
Intervention: Wald test based on fitting separate multiple logistic regression models
Number of subjects: 0
Study 10399205 — intervention group
Group type: EXPERIMENTAL
Intervention: Score test requiring fitting just the proportional odds model
Number of subjects: 0
Study 8530758 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected reassurance condition
Number of subjects: 36
Study 8530758 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected-no reassurance condition
Number of subjects: 36
Study 8530758 — intervention group
Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 36
Study 2177041 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (4 mg per 1 kg of body weight, once daily for 6 weeks)
Number of subjects: 15
Study 2177041 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 patients)
Number of subjects: 15
Study 6996516 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (three doses) during follicular phase
Number of subjects: 10
Study 6996516 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (three doses) during luteal phase
Number of subjects: 10
Study 6996516 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 10
Study 31865042 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitor (veliparib)
Number of subjects: 32
Study 30560515 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth COMPASS program (5-week web- and mobile-delivered intervention)
Number of subjects: 249
Study 28500019 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the EORTC QLQ-H&N35
Number of subjects: 10
Study 28500019 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the EORTC QLQ-H&N35
Number of subjects: 10
Study 26262586 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training plus low dose of dopamine agonists (DA)
Number of subjects: 14
Study 26262586 — intervention group
Group type: COMPARATOR
Intervention: Exercise training plus placebo
Number of subjects: 14
Study 23621675 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release diclofenac
Number of subjects: 62
Study 23621675 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen and ibuprofen
Number of subjects: 62
Study 21712706 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated dose (F) group: paclitaxel (100 mg/m(2)) and carboplatin (AUC=3) on days 1 and 8
Number of subjects: 27
Study 21712706 — intervention group
Group type: COMPARATOR
Intervention: Nonfractionated (NF) dose group: paclitaxel (200 mg/m(2)) and carboplatin (AUC=6) on day 1
Number of subjects: 27
Study 21712706 — intervention group
Group type: COMPARATOR
Intervention: NF group
Number of subjects: 27
Study 21712706 — intervention group
Group type: EXPERIMENTAL
Intervention: F group
Number of subjects: 27
Study 21712706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study 19523690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training (CAT)
Number of subjects: 120
Study 19523690 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic Environmental Supports (GES)
Number of subjects: 120
Study 19523690 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 120
Study 17524721 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-based version of the quick list
Number of subjects: 18
Study 17524721 — intervention group
Group type: COMPARATOR
Intervention: Unstructured version of the quick list
Number of subjects: 18
Study 15455406 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide 100 microg
Number of subjects: 57
Study 15455406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 11438328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.060 mg Org 30659
Number of subjects: 81
Study 11438328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.120 mg Org 30659
Number of subjects: 81
Study 11438328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.180 mg Org 30659
Number of subjects: 81
Study 11438328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.240 mg Org 30659
Number of subjects: 81
Study 11438328 — intervention group
Group type: COMPARATOR
Intervention: 0.075 mg desogestrel (reference group)
Number of subjects: 81
Study 9127118 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (MK-462)
Number of subjects: 0
Study 9127118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 0
Study 9127118 — intervention group
Group type: COMPARATOR
Intervention: 5-HT
Number of subjects: 0
Study 8246266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from CF patients with elevated serum IgG
Number of subjects: 21
Study 8246266 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG1, IgG2, or IgG4-enriched fractions
Number of subjects: 21
Study 8246266 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG3-enriched fractions from CF patients
Number of subjects: 21
Study 8246266 — intervention group
Group type: COMPARATOR
Intervention: Sera from CF patients with low serum IgG
Number of subjects: 21
Study 8246266 — intervention group
Group type: COMPARATOR
Intervention: Sera from healthy controls
Number of subjects: 21
Study 3527712 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal block
Number of subjects: 115
Study 3527712 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 115
Study 3527712 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 115
Study 31122537 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid coload at 37 °C (Group W)
Number of subjects: 60
Study 31122537 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid coload at room temperature (Group RT)
Number of subjects: 60
Study 28472240 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (gonadotropin-releasing hormone agonist) administered before and during chemotherapy
Number of subjects: 202
Study 28472240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no goserelin)
Number of subjects: 202
Study 26035199 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg venlafaxine + 60‐minute light of 7000 lux daily at 7:00 AM (venlafaxine + bright light therapy)
Number of subjects: 50
Study 26035199 — intervention group
Group type: COMPARATOR
Intervention: 150 mg venlafaxine daily at 7:00 AM
Number of subjects: 50
Study 23965217 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 21251178 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189265 (LY) 1 mg or higher doses
Number of subjects: 43
Study 21251178 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189265 (LY) 0.3 mg
Number of subjects: 43
Study 21251178 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189265 (LY) 0.05, 0.3, 1, 3, 5, or 8 mg
Number of subjects: 43
Study 21251178 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2189265 (LY)
Number of subjects: 43
Study 19254299 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary techniques for denture fabrication
Number of subjects: 0
Study 19254299 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate prescription of impression materials
Number of subjects: 0
Study 17804441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6560
Study 17804441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6560
Study 15042453 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous iliac-crest bone grafts
Number of subjects: 79
Study 15042453 — intervention group
Group type: COMPARATOR
Intervention: Allogenic fibular bone grafts
Number of subjects: 79
Study 15042453 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-level fusions
Number of subjects: 79
Study 15042453 — intervention group
Group type: EXPERIMENTAL
Intervention: One-level fusions
Number of subjects: 79
Study 15042453 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 79
Study 11119454 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients
Number of subjects: 104
Study 11119454 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 104
Study 9314089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiazac (diltiazem HCl capsule formulation)
Number of subjects: 14